{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T12:40:46Z","timestamp":1695818446497},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research Centre Egypt"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background\n<\/jats:title>\n                <jats:p>Fragile X syndrome (FXS) is the most common form of inherited intellectual disability, caused by CGG-repeats expansion (&gt;\u2009200 repeats). Premutation alleles (PM) (55\u2013200 CGG repeats) are associated with tremor ataxia syndrome (FXTAS), fragile X-associated primary ovarian insufficiency (FXPOI), and autistic problems.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To screen the frequency of premutation carriers using molecular diagnostic assays, in a cohort of Egyptian males with suspected clinical features of (FXS) checking for the presence of premutation alleles.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The current study comprised 192 Egyptian male children, 92 participants presented with intellectual disability, delayed language development, autistic-like features, behavioral difficulties, anxiety, seizures, and depression compared to 100 healthy males. All cases were subjected to clinical and neuroimaging assessments, when indicated as well as molecular analysis using methylation-specific PCR (MS-PCR) and quantitative real-time PCR (qRT-PCR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-four premutation carriers out of 92 Egyptian males (37%) of CGG repeats (55 to 200) were illustrated with elevated FMR1 mRNA expression level (<jats:italic>p<\/jats:italic>-value\u2009&lt;\u20090.001). Additionally, 2 intermediate (IM) cases (0.03%) (45\u201355 CGG repeats) showed poor increase in expression level (<jats:italic>p<\/jats:italic>-value\u2009=\u20090.02838) plus 6 full mutation (FM) patients (0.07%) with (&gt;\u2009200 CGG repeats) (<jats:italic>p<\/jats:italic>-value\u2009&lt;\u20090.001) resulted in <jats:italic>FMR1<\/jats:italic> gene silence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Molecular diagnostic assay including (MS-PCR) and (qRT-PCR) proved to be a sensitive and rapid screening tool for the detection of premutation cases. Furthermore, the presence of positive correlation between FMR1 mRNA expression levels with CGG repeats in premutation cases could serve as a potential diagnostic marker. Application of these diagnostic tools on larger number clinically suspected cases is recommended.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11845-022-03166-9","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T05:03:07Z","timestamp":1669006987000},"page":"2265-2272","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnostic value of molecular approach in screening for fragile X premutation cases"],"prefix":"10.1007","volume":"192","author":[{"given":"Miral M.","family":"Refeat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa M.","family":"El Saied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehab R.","family":"Abdel Raouf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"3166_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.716311","volume":"12","author":"J Pozo-Palacios","year":"2021","unstructured":"Pozo-Palacios J, Llamos-Paneque A et al (2021) Experiences of the molecular diagnosis of Fragile X syndrome in Ecuador. Front Psychiatry 12:716311. https:\/\/doi.org\/10.3389\/fpsyt.2021.716311","journal-title":"Front Psychiatry"},{"key":"3166_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104740","volume":"136","author":"MJ Salcedo-Arellanoa","year":"2020","unstructured":"Salcedo-Arellanoa MJ, Dufourc B et al (2020) Fragile X syndrome and associated disorders. Clinical aspects and pathology Neurobiol Dis 136:104740","journal-title":"Clinical aspects and pathology Neurobiol Dis"},{"key":"3166_CR3","first-page":"1689","volume":"14","author":"R Hagerman","year":"2021","unstructured":"Hagerman R, Sodhi DK (2021) Fragile X premutation: medications, therapy and lifestyle advice. Pharmgenomics Pers Med 14:1689\u20131699","journal-title":"Pharmgenomics Pers Med"},{"key":"3166_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3389\/fped.2020.00266","volume":"8","author":"K Johnson","year":"2020","unstructured":"Johnson K, Herring J et al (2020) Fragile X premutation associated conditions (FXPAC). Front Pediatr 8:266. https:\/\/doi.org\/10.3389\/fped.2020.00266","journal-title":"Front Pediatr"},{"issue":"1","key":"3166_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1866-1955-6-22","volume":"6","author":"F Tassone","year":"2014","unstructured":"Tassone F, Hagerman PJ et al (2014) Fragile x permutation J Neurodev Disord 6(1):22","journal-title":"Fragile x permutation J Neurodev Disord"},{"key":"3166_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/genes7100087","volume":"7","author":"I Rajan-Babu","year":"2016","unstructured":"Rajan-Babu I, Chong SS (2016) Molecular correlates and recent advancements in the diagnosis and screening of FMR1-related disorders. Genes 7:87","journal-title":"Genes"},{"key":"3166_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1373\/clinchem.2015.244681","volume":"62","author":"SM Aliaga","year":"2016","unstructured":"Aliaga SM, Slater HR et al (2016) Identification of males with cryptic fragile X alleles by methylation-specific quantitative melt analysis. Clin Chem 62:343\u2013352","journal-title":"Clin Chem"},{"key":"3166_CR8","doi-asserted-by":"publisher","unstructured":"Field M, Dudding-Byth T et al (2019) Significantly elevated FMR1 mRNA and mosaicism for methylated premutation and full mutation alleles in two brothers with autism features referred for fragile X testing. Int J Mol Sci 20: 3907. https:\/\/doi.org\/10.3390\/ijms20163907","DOI":"10.3390\/ijms20163907"},{"key":"3166_CR9","first-page":"16","volume":"10","author":"H Megahed","year":"2021","unstructured":"Megahed H, Shaheen O et al (2021) Fragile X syndrome clinical and associated comorbidities. Middle East J Med Genet 10:16\u201323","journal-title":"Middle East J Med Genet"},{"issue":"4","key":"3166_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.nrl.2014.10.009","volume":"32","author":"A Pugin","year":"2017","unstructured":"Pugin A, Faundes V et al (2017) Clinical, molecular, and pharmacological aspects of FMR1-related disorders. Neurologia 32(4):241\u2013252","journal-title":"Neurologia"},{"key":"3166_CR11","doi-asserted-by":"publisher","first-page":"17065","DOI":"10.1038\/nrdp.2017.65","volume":"29","author":"R Hagerman","year":"2017","unstructured":"Hagerman R, Berry-Kravis E et al (2017) Fragile X syndrome. Nat Rev Dis Primers 29:17065","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"3166_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226811","volume":"14","author":"K Kim","year":"2019","unstructured":"Kim K, Hessl D, Randol JL et al (2019) Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions. PLoS ONE 14(12):e0226811. https:\/\/doi.org\/10.1371\/journal.pone.0226811","journal-title":"PLoS ONE"},{"key":"3166_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1089\/gte.2006.0508","volume":"11","author":"B-N Rosales-Reynoso","year":"2007","unstructured":"Rosales-Reynoso B-N et al (2007) PCR Approach for detection of fragile X syndrome and Huntington disease based on modified DNA: limits and utility. Genet Test 11:153\u2013159","journal-title":"Genet Test"},{"key":"3166_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.fsigen.2014.03.011","volume":"11","author":"E Sauer","year":"2014","unstructured":"Sauer E, Madea B et al (2014) An evidence based strategy for normalization of quantitative PCR data from miRNA expression analysis in forensically relevant body fluids. Forensic Sci Int Genet 11:174\u2013181","journal-title":"Forensic Sci Int Genet"},{"key":"3166_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13229-019-0271-7","volume":"10","author":"EK Baker","year":"2019","unstructured":"Baker EK, Arpone M et al (2019) Incomplete silencing of full mutation alleles in males with fragile X syndrome is associated with autistic features. Mol Autism 10:21","journal-title":"Mol Autism"},{"key":"3166_CR16","doi-asserted-by":"crossref","unstructured":"Hagerman RJ, Protic D et al (2018) Fragile X-associated neuropsychiatric disorders (FXAND). Front Psychiatry Nov 13;9:564","DOI":"10.3389\/fpsyt.2018.00564"},{"key":"3166_CR17","doi-asserted-by":"publisher","unstructured":"Rajaratnam A, Shergill et al (2017) Fragile X syndrome and fragile X-associated disorders. F1000 Faculty Rev 2112. https:\/\/doi.org\/10.12688\/f1000research.11885.1","DOI":"10.12688\/f1000research.11885.1"},{"key":"3166_CR18","doi-asserted-by":"crossref","unstructured":"Crawford H, Abbeduto L et al (2020). Fragile X syndrome: an overview of cause, characteristics, assessment and management. Paediatr Child Health","DOI":"10.1016\/j.paed.2020.08.007"},{"key":"3166_CR19","unstructured":"Hunter JE, Berry-Kravis E et al (2019) FMR1 disorders. Gene Reviews 1\u201338"},{"issue":"4","key":"3166_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/14737159.2020.1729744","volume":"20","author":"D Kumari","year":"2020","unstructured":"Kumari D, Usdin K (2020) Molecular analysis of FMR1 alleles for fragile X syndrome diagnosis and patient stratification. Expert Rev Mol Diagn 20(4):363\u2013365. https:\/\/doi.org\/10.1080\/14737159.2020.1729744","journal-title":"Expert Rev Mol Diagn"},{"key":"3166_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejmhg.2015.11.001","volume":"17","author":"HAH Omar","year":"2016","unstructured":"Omar HAH, Kamal TM et al (2016) Molecular characterization of X chromosome fragility in idiopathic mental retardation. Egypt J Med Hum Genet 17:165\u2013172","journal-title":"Egypt J Med Hum Genet"},{"key":"3166_CR22","first-page":"132","volume":"7","author":"HM Abd El-Ghanya","year":"2019","unstructured":"Abd El-Ghanya HM, Ehssan EA et al (2019) Fragile X syndrome: diagnosis by molecular characterization of FMR1 gene and clinical correlation. Middle East J Med Genet 7:132\u2013138","journal-title":"Middle East J Med Genet"},{"key":"3166_CR23","doi-asserted-by":"crossref","unstructured":"Brown SSG, Basu S et al (2018) Age-related functional brain changes in FMR1 premutation carriers NeuroImage: Clinical 17:761\u2013767","DOI":"10.1016\/j.nicl.2017.12.016"},{"key":"3166_CR24","doi-asserted-by":"crossref","unstructured":"Jiraanonta P, Swehaa SR et al (2017) Clinical and molecular correlates in fragile X premutation females. eNeurological Sci 7;49\u201356","DOI":"10.1016\/j.ensci.2017.04.003"},{"key":"3166_CR25","doi-asserted-by":"crossref","unstructured":"Agam G, Levine J (2020) Neuroprotective effects of lithium in\u00a0neuropsychiatric\u00a0 disorders. In Neuroprotection in Autism, Schizophrenia and Alzheimer's Disease 209\u2013241","DOI":"10.1016\/B978-0-12-814037-6.00006-9"},{"key":"3166_CR26","doi-asserted-by":"publisher","unstructured":"Field M, Dudding-Byth T et al (2019) Significantly elevated FMR1 mRNA and mosaicism for methylated premutation and full mutation alleles in two brothers with autism features referred for fragile X testing. Int. J. Mol. Sci. 20:3907. https:\/\/doi.org\/10.3390\/ijms20163907","DOI":"10.3390\/ijms20163907"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03166-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-022-03166-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03166-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T01:06:03Z","timestamp":1695776763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-022-03166-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["3166"],"URL":"https:\/\/doi.org\/10.1007\/s11845-022-03166-9","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,21]]},"assertion":[{"value":"24 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participants were recruited from Neuro-Rehabilitation and learning disabilities clinic, at Centre of Excellence of Medical Research, National Research Centre, Cairo, Egypt, and an informed consent was signed from the accompanying parents or guardian approved by the Medical Research Ethics Committee, NRC. The current study was granted by an ethical committee of Medical Research of Excellence centre, National Research Centre (NRC), Cairo, Egypt.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}